Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Flutamide
Drug ID BADD_D00943
Description An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Indications and Usage For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
Marketing Status Prescription; Discontinued
ATC Code L02BB01
DrugBank ID DB00499
KEGG ID D00586
MeSH ID D005485
PubChem ID 3397
TTD Drug ID D0Y0SW
NDC Product Code 60429-272; 80725-600; 49884-753; 44657-0056; 53104-7536; 12780-4750; 44657-0048; 69097-915
Synonyms Flutamide | Niftolid | Niftolide | Chimax | Cytamid | Eulexin | Euflex | Drogenil | Eulexine | Fluken | Flulem | Flumid | Fluta 1A Pharma | Fluta-cell | Fluta cell | Flutacell | Fluta-GRY | Fluta GRY | FlutaGRY | Flutamin | Flutandrona | Flutaplex | Flutexin | Fugerel | Grisetin | Novo-Flutamide | Novo Flutamide | NovoFlutamide | Oncosal | PMS-Flutamide | PMS Flutamide | Prostacur | Prostica | Prostogenat | SCH-13521 | SCH 13521 | SCH13521 | Testotard | Apimid | Apo-Flutamide | Apo Flutamide | ApoFlutamide
Chemical Information
Molecular Formula C11H11F3N2O3
CAS Registry Number 13311-84-7
SMILES CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityCytochrome P450 3A4P08684T378488014883; 9759603
HepatotoxicityCytochrome P450 1A1P04798Not Available8014883; 9759603
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Galactorrhoea05.03.04.002; 21.05.02.002--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematuria24.07.01.047; 20.02.01.006--
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatic encephalopathy09.01.03.006; 17.13.01.003--Not Available
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.004--Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hypertension24.08.02.001--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Injection site irritation08.02.03.027; 12.07.03.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Loss of libido19.08.03.003--Not Available
Lung disorder22.02.07.001--Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Methaemoglobinaemia01.05.01.002--
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages